Gregory W. Roloff, MD, on Confirming Durable Efficacy of Brexu-Cel and Maintenance Therapy in B-ALL

Commentary
Video

The chief hematology/oncology fellow at University of Chicago discussed real-world experience data and new analyses of patients with B-cell acute lymphoblastic leukemia treated with brexu-cel.

“The main question that we really wanted to answer after we established that these remissions were durable, was, how do we keep them there? And how do we maintain a disease-free state? So, we performed uni- and multivariate analysis to see, and, ultimately, confirm, that the use of consolidation and maintenance therapies... signaled for superior progression free survival."

Real-world, clinical use of brexucabtagene autoleucel (Tecartus; Kite) in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) has demonstrated a 90% complete response rate and 82% minimal residual disease negativity rate. These data, across sites in the United States, are from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) study presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California, by Gregory Roloff, MD, chief hematology/oncology fellow, University of Chicago.

Investigators, including Roloff, also observed a benefit in progression-free survival in patients that also received maintenance or consolidation therapy, In terms of safety, there were low rates of severe cytokine release syndrome but a 32% rate of grade 3-4 immune effector cell-associated neurotoxicity syndrome.

CGTLive spoke with Roloff to learn more about the new real-world data presented. He also discussed the positive outcomes observed with patients with central nervous system involvement of their leukemia and leukemic infiltration of the spinal canal, a population that was excluded from the pivotal ZUMA-3 trial (NCT02614066).

Click here to view more coverage of the 2023 ASH meeting.

REFERENCE
Roloff GW, Aldoss I, Kopmar NE, et al. Brexucabtagene autoleucel in adults with relapsed/refractory B-cell ALL: Outcomes and novel insights from the real-world outcomes collaborative of CAR T in adult ALL (ROCCA). Presented at: ASH 2023 Annual Meeting & Exposition. December 9-12; San Diego, CA. Abstract 1030
Related Videos
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
© 2024 MJH Life Sciences

All rights reserved.